QIAGEN Wins the US FDA Clearance for QIAstat-Dx GI Panels on QIAstat-Dx Rise Syndromic Testing System

Shots:

• The US FDA has cleared all QIAstat-Dx GI Panels for use on the QIAstat-Dx Rise automated syndromic testing system
• The clearance enables laboratories to run both GI and respiratory panels on the high-throughput platform, which can process up to 160 tests/day, run 16 samples per batch, and deliver results in ~1hr. using real-time PCR
• The GI Panel 2 detects 16 bacterial, viral, and parasitic pathogens from a single stool sample, while Mini B & Mini B&V panels provide targeted detection of five pathogens, incl. STEC, expanding QIAGEN’s FDA-cleared QIAstat-Dx menu to six panels

Ref: Businesswire | Image: QIAGEN | Press Release

Related News: QIAGEN to Acquire Parse Biosciences for ~$280M

PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com